WATERTOWN, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals Inc., a second generation RNA interference (RNAi) company developing novel therapeutics utilizing its proprietary Dicer Substrate Technology™ and Dicer Substrate siRNA (DsiRNA) molecules, announced today that Kyowa Hakko Kirin Co., Ltd. (TSE: 4151) (KHK) has recognized the successful achievement of an in vivo activity milestone in the development of its second collaborative therapeutic oncology candidate. This achievement triggers an undisclosed milestone payment to Dicerna.
